Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This project will examine effects of bupropion extended release (XL) at a dose of 300mg/day
for cocaine abstinence among persons receiving methadone for the treatment of opioid use
disorder. Participants also earned financial incentives for providing urine samples that
tested negative for cocaine. Bupropion was examined for this purpose because of its
previously demonstrated efficacy and safety as well as its pharmacological actions at
dopamine systems. Participants were randomly assigned to bupropion XL vs. placebo and
received different incentive schedules depending on whether they demonstrated abstinence from
cocaine early in the study. Outcomes were tracked over a 6-month time frame and the
overarching hypothesis was that bupropion (as compared to placebo) would increase the number
of urine samples testing negative for cocaine, independent of whether participants
demonstrated abstinence from cocaine early in the study.